Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China

Tumor Biology

Volumn 37, Issue 8, 2016, Pages 10339-10348

  Hao, Mengze ^a   Zhao, Gang ^a   Du, Xiaoling ^a   Yang, Yun ^a   Yang, Jilong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Metastatic melanoma; Overall survival; Predictor; Prognosis; Progression free survival

Indexed keywords

LACTATE DEHYDROGENASE;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHINA; CUTANEOUS MELANOMA; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME; VISCERAL METASTASIS; ADULT; AGED; KAPLAN MEIER METHOD; MELANOMA; METASTASIS; MIDDLE AGED; MORTALITY; MUCOSA; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SKIN TUMOR;

ADULT; AGED; CHINA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MUCOUS MEMBRANE; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 84957537143     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-4914-4     Document Type: Article

References (43)

1. Kosary CL, Altekruse SF, Ruhl J, Lee R, Dickie L. Clinical and prognostic factors for melanoma of the skin using seer registries: collaborative stage data collection system, version 1 and version 2. Cancer. 2014;120 Suppl 23:3807–14.
2. Korta DZ, Saggar V, Wu TP, Sanchez M. Racial differences in skin cancer awareness and surveillance practices at a public hospital dermatology clinic. J Am Acad Dermatol. 2014;70:312–7.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
4. Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson 3rd WE, et al. Melanoma, version 4. 2014. J Natl Compr Canc Netw. 2014;12:621–9.
5. Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014;28:1005–11.
6. Howlader N NA, Krapcho M, Neyman N, Aminou R, Waldron W, et al. editors. Available from: SEER cancer statistics review, 1975–2009, National Cancer Institute. Bethesda, md. Available from: http://seer.cancer.gov/csr/1975-2009-pops09/. 2013
7. Zhu H, Dong D, Li F, Liu D, Wang L, Fu J, et al. Clinicopathologic features and prognostic factors in patients with non-cutaneous malignant melanoma: s single-center retrospective study of 71 cases. Int J Dermatol. 2015;54(12):1390–5.
8. Song X, Zhao Z, Barber B, Farr AM, Ivanov B, Novich M. Overall survival in patients with metastatic melanoma. Curr Med Res Opin. 2015;31(5):987–91.
9. Zhong J, Zhou JN, Xu FP, Shang JQ. Diagnosis and treatment of anorectal malignant melanoma—a report of 22 cases with literature review. Chin J Cancer. 2006;25:619–24.
10. Debarbieux S, Duru G, Dalle S, Beatrix O, Balme B, Thomas L. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection. Br J Dermatol. 2007;157:58–67.
11. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–206.
12. Bostanci O, Kartal K. Liver metastases of unknown primary. Malignant Melanoma. 2014;2014:131708.
13. Erez A, Shental O, Tchebiner JZ, Laufer-Perl M, Wasserman A, Sella T, et al. Diagnostic and prognostic value of very high serum lactate dehydrogenase in admitted medical patients. Isr Med Assoc J. 2014;16:439–43.
14. Akcay MN. Metastatic disease in the breast. Breast. 2002;11:526–8.
15. Moreno-Ramirez D, Ojeda-Vila T, Rios-Martin JJ, Nieto-Garcia A, Ferrandiz L. Role of age and sex in the diagnosis of early-stage malignant melanoma: a cross-sectional study. Acta Derm Venereol. 2015;95(8):940–2.
16. Haas A, Pinter O, Papaefthymiou G, Weger M, Berghold A, Schrottner O, et al. Incidence of radiation retinopathy after high-dosage single-fraction gamma knife radiosurgery for choroidal melanoma. Ophthalmology. 2002;109:909–13.
17. Philippart P, da Costa PM, Heymans O, Pector JC, de Saint-Aubin N, Andry G. Metastatic involvement of ceco-appendicular segment: a diagnosis of right lower quadrant abdominal pain in patient receiving chemotherapy. Hepato-Gastroenterol. 2000;47:1627–9.
18. Avery-Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, et al. P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer. 2011;11:203.
19. Cascinelli N, Heerlyn M, Schneeberger A, Kuwert C, Slominski A, Armstrong C, et al. What is the most promising strategy for the treatment of metastasizing melanoma? Exp Dermatol. 2000;9:439–51.
20. Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X. The incidences and mortalities of major cancers in China, 2010. Chin J Cancer. 2014;33(8):402–5.
21. Eggermont AM, Robert C. New drugs in melanoma: it’s a whole new world. Eur J Cancer. 2011;47:2150–7.
22. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma? Lancet Oncol. 2013;14:e60–9.
23. Cybulska-Stopa B, Skoczek M, Ziobro M, Switaj T, Falkowski S, Morysinski T, et al. Results of systemic treatment of cutaneous melanoma in inoperable stage iii and iv. Contemp Oncol (Pozn). 2012;16:532–45.
24. Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;7:572–6.
25. Shields CL, Shields MV, Viloria V, Pearlstein H, Say EA, Shields JA. Iridocorneal endothelial syndrome masquerading as iris melanoma in 71 cases. Arch Ophthalmol. 2011;129:1023–9.
26. Chi Z, Li S, Sheng X, Si L, Cui C, Han M, et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer. 2011;11:85.
27. Lepper W, Shivalkar B, Rinkevich D, Belcik T, Wei K. Assessment of the vascularity of a left ventricular mass using myocardial contrast echocardiography. J Am Soc Echocardiogr. 2002;15:1419–22.
28. Fujii K, Komurasaki Y, Kanno Y, Ohgou N. Unilateral exophthalmos due to orbital metastasis from a contralateral intraocular melanoma. Eur J Dermatol. 1998;8:343–6.
29. Rutkowski P, Debiec-Rychter M, Ruka W. Gastrointestinal stromal tumors: key to diagnosis and choice of therapy. Mol Diagn Ther. 2008;12:131–43.
30. Dabouz F, Barbe C, Lesage C, Le Clainche A, Arnoult G, Hibon E, et al. Clinical and histological features of head and neck melanoma: a population-based study in France. Br J Dermatol. 2014;172(3):707–15.
31. Andersen PS, Chakera AH, Thamsborg AK, Kolle SF, Schmidt G, Klyver H, et al. Recurrence and survival after neck dissections in cutaneous head and neck melanoma. Dan Med J. 2014;61:A4953.
32. Franzke A, Probst-Kepper M, Buer J, Duensing S, Hoffmann R, Wittke F, et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer. 1998;78:40–5.
33. Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. 2005;93:273–8.
34. Pan Y, Haydon AM, McLean CA, McDonald PB, Kelly JW. Prognosis associated with cutaneous melanoma metastases. Australas J Dermatol. 2015;56:25–8.
35. Brand CU, Ellwanger U, Stroebel W, Meier F, Schlagenhauff B, Rassner G, et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer. 1997;79:2345–53.
36. Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol. 1998;16:1103–11.
37. Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of eastern cooperative oncology group trials. J Clin Oncol. 2000;18:3782–93.
38. Bartlett EK, Karakousis GC. Current staging and prognostic factors in melanoma. Surg Oncol Clin N Am. 2015;24:215–27.
39. Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, et al. S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage iv melanoma. J Clin Oncol. 1999;17:1891–6.
40. Diem S, Kasenda B, Martin-Liberal J, Lee A, Chauhan D, Gore M, et al. Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur J Cancer. 2015;51:2785–91.
41. Unger JM, Flaherty LE, Liu PY, Albain KS, Sondak VK. Gender and other survival predictors in patients with metastatic melanoma on southwest oncology group trials. Cancer. 2001;91:1148–55.
42. Joosse A, Collette S, Suciu S, Nijsten T, Lejeune F, Kleeberg UR, et al. Superior outcome of women with stage i/ii cutaneous melanoma: pooled analysis of four European organisation for research and treatment of cancer phase iii trials. J Clin Oncol. 2012;30:2240–7.
43. Joosse A, Collette S, Suciu S, Nijsten T, Patel PM, Keilholz U, et al. Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage iii to iv melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials. J Clin Oncol. 2013;31:2337–46.